Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06355999 · ClinicalTrials.gov registry record · NA
Levari Exp.20: 2D - Partial Feedback
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT06355999: Completed NA study, sponsored by Brigham and Women's Hospital.
NCT06355999 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06355999, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormality and by the feedback that observers (Os) receive. If abnormal spots are rare (low prevalence), Os will tend to become more conservative about calling spots abnormal. In this experiment, Os see items defined by color and shape. They are looking for one combination (bumpy green). Bumpy green targets can be common (50% prevalence) or rare (10%). Os in one group will get feedback about their responses based on color. The other group will receive feedback based on shape. The investigators will look for effects of prevalence and of the type of feedback. The goal is to better understand perceptual decisions in settings like clinical evaluation of skin lesions.
Primary Outcome
Participants are presented with visual stimuli from a 10 by 10 set of 100 possibilities. There are 10 levels of color (blue to green) and 10 levels of shape (smooth="Bouba" to bumpy = "Kiki", fully crossed with each other. Participants are asked to state whether an item is or is not a "green Kiki" target. For each of the 100 items, the primary outcome measure is the percentage of time that the specific item is called "Green Kiki" target.
Interventions
- BEHAVIORAL Color Feedback
- BEHAVIORAL Shape Feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2021-06-01 |
| Phase | NA |
What the finished NCT06355999 record still lists
NCT06355999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Color Feedback is the first listed.
NCT06355999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06355999 about?
NCT06355999 is a clinical study titled "Levari Exp.20: 2D - Partial Feedback". Suppose that observers are trying to classify a spot on the skin as normal or abnormal and suppose that the two attributes that are important are the color and shape of the spot. The investigators have found that perceptual decisions of this short are shaped by the prevalence of the target abnormali...
What is the current status of trial NCT06355999?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2021-05-01. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT06355999?
The interventions under investigation include: Color Feedback (BEHAVIORAL), Shape Feedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT06355999?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06355999's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI